15
Participants
Start Date
April 19, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Seraph-100 + State of the Art Care
Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
State of the Art Care
"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
Trinity Health Mid Atlantic-SMMC, Langhorne
George Washington University, Washington D.C.
Southeast Georgia Health System, Inc., Brunswick
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
University of Texas Southwestern Medical Center, Dallas
Methodist Hospital, San Antonio
University of Texas Health Science Center at San Antonio (UT Health San Antonio), San Antonio
Good Samaritan Hospital, Corvallis
Lead Sponsor
Uniformed Services University of the Health Sciences
FED
ExThera Medical Corporation
INDUSTRY